A 2025 UC San Diego observational study of more than 6,800 colon cancer patients reported that 15% of patients using GLP-1 receptor agonist medications (such as Ozempic or Wegovy) died within five years versus 37% of non-users, after adjustment for age, cancer severity, and other medical conditions; the association was strongest in patients with body mass index (BMI) âĨ35.
November 11, 2025
medium
statistical
Summary of the study's main adjusted five-year mortality comparison and subgroup effect by obesity level.
GLP-1 receptor agonist medications are known to reduce systemic inflammation, lower circulating insulin levels, and promote weight loss.
high
biological
Mechanistic effects commonly attributed to GLP-1 receptor agonists relevant to metabolic health.